Search Results

India Tender Notice: Tablet Tadalafil 20 Mg

• Source: Indian eGov Newswire (India), December 12, 2024, 1pp

Record details

Tadalafil Industry 2019 Global Market Growth, Size, Share, Insights, Supply, Drivers, Demand, Outlook, Trends and Forecasts 2025

• Authors : By:siddhis

• Source: iCrowdNewswire (USA), January 17, 2019 News, 5pp

Record details

Tadalafil 2019 Market Size, Share and Global Growth Analysis and Forecast 2025

• Authors : By:Retu mittal

• Source: iCrowdNewswire (USA), February 14, 2019 News, 6pp

Record details

Global and Chinese Tadalafil Industry 2009-2019 Market Research Report Now Available at LifeScienceIndustryResearch.com

• Source: PRWeb (USA), July 28, 2014, 3pp

Record details

Tadalafil Market 2020 Global Industry Current Trends, Top Companies, Application, Growth Factors, Development and Forecast to 2026 Research Report

• Authors : By:Sabmit Kumar

• Source: iCrowdNewswire (USA), April 14, 2020 News, 6pp

Record details

Tadalafil Market 2019 Industry Size, Share, Segmentation, Expanding Trends and Forecast Analysis 2025

• Authors : By:OrianResearchReports

• Source: iCrowdNewswire (USA), February 27, 2019 News, 4pp

Record details

Tadalafil (Cialis) In The Treatment Of Erectile Dysfunction

• Authors : By:Robert M Coward, MD and Culley C Carson III, MD as part of Beyond the Abstract on UroToday.com.

• Source: Medical News Today (England), May 30, 2009 Erectile Dysfunction / Premature Ejaculation, 3pp

Record details

Tadalafil (Adcirca): Phosphodiesterase type 5 inhibitor approved for the treatment of pulmonary arterial hypertension (WHO Group I)

• Authors : By:Formulary journal staff

• Source: Formulary (USA), July 1, 2009 FDA drug approvals, 5pp

Record details

Tadalafil (Adcirca): Phosphodiesterase type 5 inhibitor approved for the treatment of pulmonary arterial hypertension (WHO Group I)

• Authors : By:Formulary journal staff

• Source: Formulary (USA), July 1, 2009 FDA drug approvals, 5pp

Record details

Tadalafil (Cialis): A phosphodiesterase type 5 inhibitor for the treatment of benign prostatic hyperplasia

• Authors : By:Formulary Staff

• Source: Formulary (USA), January 1, 2012 FDA Approvals, 5pp

Record details